Optometrist Vance Thompson Vision Sioux Falls, South Dakota, United States
Disclosure(s): No relevant disclosure to display
Disclosure(s):
Mitchel Ibach, OD: No relevant disclosure to display
Traditional pharmaceutical and surgical glaucoma treatment drawbacks led to the arrival of Minimally Invasive Glaucoma surgeries (MIGs). Due to an excellent safety profile coupled with at worst modest efficacy, MIGs has been labeled one of the bigger breakthroughs in glaucoma treatment. This lecture will provide an in-depth review of current and future MIGs options and breakdown the options based on the target outflow pathway.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Answer the question: Why MIGs?
Review currently pharmaceutical and surgical glaucoma treatment pitfalls
Study each of the MIGs options in the trabecular meshwork, suprachoroidal, and sub-conjunctival sub-sets
Compare and contrast options by using published data on safety, efficacy, and medication lowering
Learn how each surgery/device fits for certain patient types, as well as introduce combining procedures
Understand guidelines and protocols for post-operative management of MIGs